AIRC-MFAG-22950 - PHENOMENA (DSB.AD008.587)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto di tecnologie biomediche (ITB)

Responsabile di progetto

FRANCESCA COLOMBO
Telefono: 0226422705
E-mail: francesca.colombo@itb.cnr.it

Abstract

About one quarter of cancer patients receiving opioid analgesia do not benefit from this therapy. Additionally, a variable percentage of patients treated with opioids for cancer pain experience unpleasant side effects (e.g. nausea and vomiting).Finding reliable markers of drug efficacy and toxicity assumes pivotal importance. With a genome-wide pharmacogenomic approach we will disclose the complex genetic profile that affects individual response to opioid therapy for cancer pain and confers individual risks of developing nausea- vomiting side effects. In addition, this study will be the first to investigate the pharmacometabolomics of opioid treatment and to combine this biochemical information with genomics data, to elucidate the functional roles of the identified genetic variations. My team will use machine-learning algorithms to integrate these omics data in order to identify novel predictors of efficacy and toxicity of opioid analgesics. By the end of the project, we will have defined integrated genetic-metabolic profiles associated with opioid response and nausea-vomiting side effects, providing novel markers to be tested for clinical utility in independent patient series.

Obiettivi

The objective of this project is to combine genome-wide genotyping and metabolic data, using machine learning algorithms, to identify clinically relevant markers for the tailored opioid treatment of cancer patients.
We expect to set the foundation for the pharmacogenomics and pharmacometabolomics of opioid therapy in cancer patients. Moreover, we expect to identify new genetic and metabolic markers, or combinations of them, explaining the interindividual variability in opioid response (in terms of efficacy and toxicity).
This project will identify new predictive markers of opioid response and toxicity, thus providing new tools for the personalized management of advanced cancer patients receiving opioid analgesia, with the aim of improving their quality of life.

Data inizio attività

02/01/2020

Parole chiave

Palliative care, Pharmacogenetics/Pharmacogenomics, Side effects

Ultimo aggiornamento: 28/01/2025